A. Dodero

发表

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

P. Zinzani, D. Degl'innocenti, P. Corradini, 2016, Journal of Hematology & Oncology.

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

T. Barbui, P. Valagussa, A. Rambaldi, 2006, Leukemia.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma

W. Chan, P. Campbell, D. Leongamornlert, 2019, American journal of hematology.

breast cancer and donor lymphocyte infusions for patients with metastatic renal and Nonmyeloablative conditioning followed by hematopoietic cell allografting

C. Voena, A. Zaniboni, C. Bordignon, 2013 .

Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO study

R. Fanin, P. Mazza, M. Martelli, 2012, Annals of Hematology.

Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.

C. Carlo-Stella, V. Montefusco, M. Milanesi, 2005, Experimental hematology.

Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation.

B. Sarina, F. Maura, V. Montefusco, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma: A Single-Institution Phase II Study

G. Cocconi, S. Cascinu, R. Camisa, 2003, American journal of clinical oncology.

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

M. Boccadoro, D. Caracciolo, F. Patriarca, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biology of peripheral T cell lymphomas – Not otherwise specified: Is something finally happening?

N. Bolli, F. Maura, C. Carniti, 2016 .

Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi

R. Bruno, A. Santoro, M. Paulli, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival

P. Corradini, A. Guidetti, S. Viviani, 2019, Leukemia & lymphoma.

Murine dendritic cells generated under serum-free conditions have a mature phenotype and efficiently induce primary immune responses.

H. Veelken, M. Follo, M. Warncke, 2006, Journal of immunological methods.

Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma.

A. Alessi, P. Corradini, L. Farina, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Integration of Transcriptional and Mutational Data improves the Stratification of 1 Peripheral T-Cell Lymphoma 2

Giancarlo, P. Campbell, D. Leongamornlert, 2019 .

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer.

C. Voena, A. Zaniboni, C. Bordignon, 2002, Blood.

Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T‐cell lymphoma: A FIL phase 2 study

P. Zinzani, P. Corradini, S. Volpetti, 2022, Hematological oncology.

Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.

G. Bonadonna, M. Di Nicola, S. Siena, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon wool-adherent mature cells.

G. Bonadonna, M. Di Nicola, S. Siena, 1994, Bone marrow transplantation.

Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.

A. Pileri, C. Voena, M. Ladetto, 2002, Blood.

Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy

S. Antinori, M. Corbellino, V. Montefusco, 2012, Transplant infectious disease : an official journal of the Transplantation Society.

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

P. Corradini, A. Guidetti, L. Farina, 2016 .

Allogeneic Stem‐cell Transplantation

P. Corradini, A. Dodero, 2021 .

Relapsed peripheral T-cell non-Hodgkin’s lymphomas: outcome following reduced-intensity conditioning allogeneic stem cell transplantation

F. Patriarca, L. Farina, F. Narni, 2009 .

Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide

F. Maura, V. Montefusco, P. Corradini, 2014, Leukemia & lymphoma.

Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial

A. Rossi, S. Chauvie, A. Biggi, 2012 .

Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports

P. Lampertico, R. Cairoli, V. Montefusco, 2017, Haematologica.

Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect

D. Baronciani, F. Ciceri, F. Bonifazi, 2012, Leukemia.

Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation.

R. Fanin, P. Valagussa, V. Montefusco, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)

P. Campbell, D. Leongamornlert, A. Butler, 2020, Haematologica.

Control of the specificity of T cell-mediated anti-idiotype immunity by natural regulatory T cells

J. Timmer, A. Bulashevska, H. Veelken, 2010, Cancer Immunology, Immunotherapy.

Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.

C. Lombardo, C. Carlo-Stella, M. Milanesi, 2009, Blood.

Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor

C. Carlo-Stella, F. Ravagnani, V. Montefusco, 2014, Leukemia & lymphoma.

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome

R. Fanin, R. Miceli, A. Bacigalupo, 2007, Leukemia.

Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma

L. Baldini, R. Miceli, A. Gallamini, 2014, Leukemia.

Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas

P. Corradini, N. Cieri, M. Pennisi, 2018, Bone Marrow Transplantation.

Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

J. Sancho, M. Federico, M. Ramírez, 2022, Haematologica.

infusions contribute to improve T-cell recovery malignancies: posttransplantation CD8-depleted donor lymphocyte conditioning regimen for the treatment of advanced hematologic Haploidentical stem cell transplantation after a reduced-intensity

C. Carlo-Stella, M. Milanesi, P. Longoni, 2013 .

Phase II study of sorafenib in patients with relapsed or refractory lymphoma

A. Anichini, C. Carlo-Stella, M. Di Nicola, 2012, British journal of haematology.

Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.

R. Miceli, A. Bosi, B. Sarina, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation

F. Patriarca, P. Corradini, L. Farina, 2009, Haematologica.

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed

F. Patriarca, P. Corradini, L. Farina, 2009 .

Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases

L. Giordano, A. Anichini, C. Carlo-Stella, 2014, Clinical Cancer Research.

Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies.

P. Valagussa, A. Bacigalupo, F. Ciceri, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation

R. Miceli, F. Fallanca, L. Castagna, 2010, Cancer.

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

R. Miceli, D. Rahal, F. Ricci, 2021, Haematologica.